K0706 for Patients Diagnosed With Dementia With Lewy Bodies
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of treatment with K0706 in Dementia with
Lewy Bodies (DLB).
The hypothesis is that K0706 will be safe and tolerable and that this drug will alter CSF and
plasma biomarkers in DLB. Clinical assessments of cognitive, behavioral and motor functioning
will also be evaluated. A total of 45 participants will be randomized 1:1:1 into 3 groups
(n=15/per group) to be treated with sachet of 192 mg powder of K0706 ( equivalent to 96 mg
capsule of K0706) or sachet of 384 mg powder of K0706 (equivalent to 192 capsule of K0706) or
sachet of matching placebo ( equivalent to a capsule of placebo) for 12 weeks, followed by
4-week wash-out period.